1. Home
  2. BLND vs FULC Comparison

BLND vs FULC Comparison

Compare BLND & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

N/A

Current Price

$0.99

Market Cap

257.8M

Sector

Technology

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.78

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLND
FULC
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.8M
285.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BLND
FULC
Price
$0.99
$3.78
Analyst Decision
Buy
Hold
Analyst Count
6
5
Target Price
$2.96
★ $3.67
AVG Volume (30 Days)
★ 1.6M
1.2M
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 58.33
N/A
EPS
★ N/A
N/A
Revenue
★ $123,585,000.00
N/A
Revenue This Year
$3.71
N/A
Revenue Next Year
$9.11
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.00
$2.83
52 Week High
$3.62
$15.74

Technical Indicators

Market Signals
Indicator
BLND
FULC
Relative Strength Index (RSI) 29.15 51.35
Support Level N/A $3.75
Resistance Level $1.60 $3.91
Average True Range (ATR) 0.06 0.07
MACD 0.00 0.00
Stochastic Oscillator 4.94 52.50

Price Performance

Historical Comparison
BLND
FULC

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: